14/11/2025
As biological therapies continue to evolve as valuable tools in the multimodal management of canine osteoarthritis (OA), so too does the debate pertaining to the cost:benefit conundrum. To support clinical decision-making, below is a concise evidence-based summary of Stem Cell Therapy using mesenchymal stem cells (MSC) therapy
Primary action: Regenerative + immunomodulatory
Tissue impact: Can differentiate into chondrocytes; chondroprotective
Best for: Moderate–severe OA, chronic cases, NSAID-intolerant patients
Duration: 6–18 months or longer
Dosing: Single / infrequent
Safety: Good in controlled studies
OA Role: Moderate–severe OA or refractory cases
Key Clinical Evidence in Dogs
MSC Therapy
Improvement in pain and lameness in prospective controlled trials
Harman et al., 2016
Sustained benefit reported up to 6–18+ months
(Kriston-Pál et al., 2020; Olsson et al., 2021)
Immunomodulatory effects demonstrated (reduced synovial inflammatory mediators, systemic immune activity)
(Beerts et al., 2023)
Most benefit seen in **moderate-to-advanced OA**
* Useful when NSAIDs/injectables insufficient or contraindicated
* Single or limited treatment sessions; allogeneic and off-the-shelf use supported
(Luo et al., 2021)
VetRenew supplies Allogenic Stem Cells that undergo rigorous quality controls. For more information or to discuss any case that you are considering using Stem Cell Therapy on, please feel free to reach out to us on [email protected] or [email protected]
